Homepage
Catalog of Screening Compounds
Screening Libraries
Focused and Target Libraries
Active Reference Sets
Diversity Libraries
Screening Compounds
Building blocks
Drug Discovery Services
Custom Chemistry
Medicinal chemistry
In silico Drug Design (CADD)
Discovery Biology
Animal Models
Toxicology and Safety
ADME, DMPK
Chemistry, Manufacturing and Controls
Company
News & Media
Contact us
For suppliers
Trends in discovery compounds
Homepage
>
Company
>
Media
>
Pharma News
>
2026
Pharma News, 2026
Pharma Tariffs Force Biotech Firms to Weigh Price Deals With White House
Small and midsize biotech firms face tough choices as new 100% tariffs loom. Will they strike MFN pricing deals or risk devastating financial impacts?
FDA Approves Travere's Sparsentan for Rare Kidney Scarring Disease FSGS
FDA approves Travere Therapeutics' sparsentan (Filspari) as the first drug for focal segmental glomerulosclerosis (FSGS), a rare kidney scarring disease.
AI Spots Hidden Behavior Patterns in Self-Organizing Myxococcus xanthus
Rice University researchers built a custom AI to uncover hidden behavior patterns in self-organizing bacteria, revealing early biological transition signs.
Annovis & NeuroRPM Partner on AI Platform to Track Parkinson's Symptoms
Annovis Bio partners with NeuroRPM to use an FDA-cleared AI platform for tracking Parkinson's symptoms in the ANVS-25002 study evaluating buntanetap.
Hoth Therapeutics Reports Positive GDNF Data for Fatty Liver Treatment
Hoth Therapeutics announces positive HT-VA study data showing GDNF reprograms liver fat metabolism at the genetic level, offering a novel MAFLD treatment.
GSK Withdraws Leucovorin Application Despite FDA Autism Treatment Push
GSK withdraws its application for Wellcovorin (leucovorin), recently touted by the FDA and Trump administration as a potential autism and CFD treatment.
Study Reveals Key Nucleoprotein Structure in Fatal Borna Disease Virus 1
Researchers have uncovered the 3D structure of the nucleoprotein-RNA complex in the fatal Borna disease virus 1, paving the way for targeted antivirals.
Letrozole Monotherapy Falls Short in Phase 3 Ovarian Cancer Trial (NRG)
Phase 3 NRG-GY019 trial results show letrozole monotherapy did not demonstrate non-inferiority to PC/L for progression-free survival in ovarian cancer.
EverSea Medicines to Acquire Hasten Biopharmaceuticals for $250 Million
Everest Medicines' subsidiary EverSea Medicines will acquire Hasten Biopharmaceuticals for $250m to enhance its commercial presence in the Asia Pacific.
Charles River Laboratories Set to Benefit from Biotech Funding Recovery
ClearBridge Investments highlights Charles River Laboratories (CRL) as a key holding, positioned to benefit from recovering biotech funding and research.
FDA Seeks Permanent Status for Rare Pediatric Priority Review Vouchers
The FDA and Commissioner Marty Makary propose permanently authorizing the rare pediatric disease priority review voucher program in the FY2027 budget.
TNX-4800 Lyme Disease Monoclonal Antibody Shows Safety in Phase 1 Trial
Phase 1 trial data for TNX-4800, a human monoclonal antibody preventing Lyme disease, demonstrates safety, tolerability, and lasting pharmacokinetics.
2
3
4
5
6
7
8
9
10
